Low-dose intradermal and subcutaneous versus intramuscular hepatitis B vaccination in primary non-responding hemodialysis patients

Journal of the Medical Association of Thailand

Volumn 89, Issue 10, 2006, Pages 1648-1653

  Sorkhi, Hadi ^a   Dooki, Mohammad Reza Esmaeli ^a   Ebrahimnejad, Mina Sadat ^a  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hemodialysis patients; Hepatitis B vaccination; Non responder; Re vaccination

Indexed keywords

HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HEPATITIS B; HUMAN; LOW DRUG DOSE; MALE; RANDOMIZED CONTROLLED TRIAL; REVACCINATION;

FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS; VACCINATION;

EID: 33750978169     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Tandon BN, Acharya SK, Tandon A. Epidemiology of hepatitis B virus infection in India. Gut 1996; 38(Suppl 2): S56-9.
2. Purcell RH. The discovery of the hepatitis viruses. Gastroenterology 1993; 104: 955-63.
3. Snydman DR, Bergman D, Bryan J. Hemodialysis-associated hepatitis in the United States, 1974. J Infect Dis 1977; 135: 687-91.
4. Tokars JI, Alter MJ, Favero MS, Moyer LA, Miller E, Bland LA. National surveillance of dialysis associated diseases in the United States, 1993. ASAIO J 1996; 42: 219-29.
5. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50: 1-43.
6. Crosnier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, Degos F, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, Haemodialysis patients. Lancet 1981; 1: 797-800.
7. Rodby AR, Trenholme GM. Vaccination of the dialysis patient. Semin Dial 1991; 4: 102-5
8. Girndt M, Pietsch M, Kohler H. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am J Kidney Dis 1995; 26: 454-60.
9. Andre FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989; 87(3A): 14S-20S.
10. Vlassopoulos D, Magana P, Hadjiyannakos D, Spyropoulou M, Lilis D, Stavropoulos C, et al. Factors involved in low response to HBV vaccine in health and end stage-renal failure. Nephrol Dial Transplant 1998; 13: A191
11. Ruiz P, Gomez F, Schreiber AD. Impaired function of macrophage Fc gamma receptors in end-stage renal disease. N Engl J Med 1990; 322: 717-22.
12. Stachowski J, Pollok M, Barth C, Maciejewski J, Baldamus CA. Non-responsiveness to hepatitis B vaccination in haemodialysis patients: association with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory processes in antigen presentation and recognition. Nephrol Dial Transplant 1994; 9: 144-52.
13. Docci D, Cipolloni PA, Mengozzi S, Baldrati L, Capponcini C, Feletti C. Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients: a two-year follow-up. Nephron 1992; 61: 352-3.
14. Fabrizi F, Di Filippo S, Marcelli D, Guarnori I, Raffaele L, Crepaldi M, et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. Nephron 1996; 72: 536-43.
15. Dentico P,Buongiorno R,Volpe A, Manno C, Carbone M, Proscia F, et al. Long term immunogenicity and protective efficacy of recombinant DNA yeast derive vaccine in hemodialysis patients. J Nephrol 1993; 6: 95-7.
16. Meuer SC, Dumann H, Meyer zum Buschenfelde KH, Kohler H. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1989; 1: 15-8.
17. Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994; 344: 856-7.
18. Ono K, Kashiwagi S. Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients. Nephron 1991; 58: 47-51.
19. Chang PC, Schrander-van der Meer AM, van Dorp WT, van Leer E. Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. Nephrol Dial Transplant 1996; 11: 191-3.
20. Propst T, Propst A, Lhotta K, Vogel W, Konig P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998; 32: 1041-5.
21. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, et al . Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315: 209-14.
22. Eddleston A. Modern vaccines. Hepatitis. Lancet 1990; 335: 1142-5.
23. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol 1996; 16: 95-7.
24. Marangi AL, Giordano R, Montanaro A, De Padova F, Schiavone MG, Dongiovanni G, et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis 1994; 23: 537-42.
25. Chau KF, Cheng YL, Tsang DN, Choi KS, Wong KM, Chak WL, et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am J Kidney Dis 2004; 43: 910-7.
26. Centers for Disease Control and Prevention. Outbreaks of hepatitis B virus infection among hemodialysis patients - California, Nebraska, and Texas, 1994. JAMA 1996; 275: 1394-5.
27. Bel'eed K, Wright M, Eadington D, Farr M, Sellars L. Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J 2002; 78: 538-40.
28. Whittle HC, Inskip H, Hall AJ, Mendy M, Downes R, Hoare S. Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia. Lancet 1991; 337: 747-50.
29. Miller KD, Gibbs RD, Mulligan MM, Nutman TB, Francis DP. Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults. Lancet 1983; 2: 1454-6.
30. Fabrizi F, Lunghi G, Bacchini G, Corti M, Guarnori I, Raffaele L, et al. Hepatitis G virus infection in chronic dialysis patients and kidney transplant recipients. Nephrol Dial Transplant 1997; 12: 1645-51.
31. Vlassopoulos D, Arvanitis D, Lilis D, Hatjiyannakos D, Louizou K, Hadjiconstantinou V. Complete success of intradermal vaccination against hepatitis B in advanced chronic renal failure and hemodialysis patients. Ren Fail 1997; 19: 455-60.
32. Waite NM, Thomson LG, Goldstein MB. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. J Am Soc Nephrol 1995; 5: 1930-4.
33. Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 976-82.
34. Mettang T, Schenk U, Thomas S, Machleidt C, Kiefer T, Fischer FP, et al. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. A preliminary study. Nephron 1996; 72: 192-6.
35. Suboptimal response to hepatitis B vaccine given by injection into the buttock. MMWR Morb Mortal Wkly Rep 1985; 34: 105-8, 113.